Table 3 Association of PPARD and PPARG polymorphisms with glioma risk stratified by age and sex.

From: The Impact of PPARD and PPARG Polymorphisms on Glioma Risk and Prognosis

Gene	SNP	Model	Age						Sex
			>40			≤40			Male			Female
			OR(95%CI)	P	FDR-P	OR(95%CI)	P	FDR-P	OR(95%CI)	P	FDR-P	OR(95%CI)	P	FDR-P
PPARD	rs2016520	Allele	0.66(0.50–0.88)	0.004	0.034	1.01(0.77–1.31)	0.964	0.970	0.82(0.64–1.06)	0.130	0.455	0.82(0.61–1.09)	0.170	0.476
		Co-dominant	0.48(0.22–1.06)	0.070	0.173	0.90(0.45–1.79)	0.765	0.970	0.78(0.4–1.51)	0.460	0.855	0.54(0.24–1.19)	0.124	0.476
			0.61(0.43–0.88)	0.008	0.047	1.08(0.75–1.55)	0.675	0.970	0.74(0.53–1.04)	0.084	0.370	0.89(0.61–1.29)	0.526	0.757
		Dominant	0.60(0.42–0.84)	0.004	0.034	1.05(0.74–1.49)	0.774	0.970	0.75(0.54–1.03)	0.079	0.370	0.83(0.58–1.19)	0.312	0.624
		Recessive	0.59(0.27–1.28)	0.179	0.376	0.87(0.45–1.69)	0.678	0.970	0.89(0.47–1.70)	0.730	0.902	0.56(0.26–1.23)	0.149	0.476
		Additive	0.65(0.48–0.87)	0.004	0.034	1.01(0.76–1.33)	0.955	0.970	0.81(0.62–1.06)	0.119	0.454	0.81(0.60–1.09)	0.164	0.476
PPARD	rs67056409	Allele	0.65(0.49–0.86)	0.003	0.034	1.03(0.80–1.34)	0.811	0.970	0.80(0.62–1.03)	0.088	0.370	0.85(0.64–1.14)	0.276	0.580
		Co-dominant	0.40(0.19–0.85)	0.017	0.071	0.99(0.5–1.96)	0.969	0.970	0.73(0.38–1.41)	0.347	0.855	0.54(0.25–1.16)	0.112	0.476
			0.67(0.46–0.96)	0.027	0.095	1.12(0.78–1.6)	0.544	0.970	0.73(0.52–1.02)	0.069	0.370	0.97(0.67–1.41)	0.883	0.883
		Dominant	0.62(0.44–0.88)	0.007	0.047	1.10(0.78–1.55)	0.596	0.970	0.73(0.53–1.01)	0.058	0.370	0.90(0.63–1.29)	0.562	0.757
		Recessive	0.47(0.22–0.98)	0.045	0.135	0.93(0.48–1.82)	0.842	0.970	0.84(0.45–1.59)	0.595	0.855	0.54(0.26–1.15)	0.111	0.476
		Additive	0.65(0.49–0.86)	0.003	0.034	1.05(0.79–1.39)	0.732	0.970	0.79(0.61–1.03)	0.082	0.370	0.85(0.63–1.13)	0.264	0.580
PPARD	rs1053049	Allele	0.68(0.51–0.91)	0.009	0.047	0.89(0.68–1.17)	0.407	0.970	0.76(0.59–0.99)	0.041	0.370	0.80(0.60–1.08)	0.143	0.476
		Co-dominant	0.41(0.18–0.93)	0.033	0.107	0.80(0.41–1.57)	0.518	0.970	0.63(0.33–1.21)	0.163	0.527	0.56(0.25–1.25)	0.159	0.476
			0.71(0.50–1.03)	0.069	0.173	0.88(0.61–1.26)	0.473	0.970	0.73(0.52–1.02)	0.065	0.370	0.85(0.58–1.23)	0.385	0.703
		Dominant	0.67(0.47–0.95)	0.024	0.092	0.86(0.61–1.22)	0.406	0.970	0.71(0.51–0.98)	0.040	0.370	0.80(0.56–1.15)	0.232	0.573
		Recessive	0.47(0.21–1.05)	0.065	0.173	0.85(0.44–1.63)	0.625	0.970	0.72(0.39–1.36)	0.315	0.855	0.60(0.27–1.32)	0.204	0.536
		Additive	0.68(0.51–0.91)	0.010	0.047	0.89(0.67–1.17)	0.389	0.970	0.76(0.59–0.99)	0.040	0.370	0.80(0.59–1.08)	0.142	0.476
PPARD	rs2206030	Allele	1.04(0.82–1.33)	0.726	0.828	1.10(0.86–1.40)	0.446	0.970	1.09(0.87–1.37)	0.460	0.855	1.07(0.83–1.38)	0.605	0.757
		Co-dominant	1.11(0.68–1.81)	0.683	0.820	1.25(0.75–2.07)	0.391	0.970	1.19(0.74–1.91)	0.471	0.855	1.14(0.69–1.89)	0.613	0.757
			1.29(0.85–1.96)	0.232	0.424	0.97(0.65–1.44)	0.866	0.970	1.13(0.78–1.65)	0.516	0.855	1.10(0.72–1.69)	0.659	0.762
		Dominant	1.23(0.83–1.83)	0.304	0.532	1.04(0.71–1.51)	0.848	0.970	1.15(0.80–1.64)	0.448	0.855	1.11(0.74–1.67)	0.602	0.757
		Recessive	0.93(0.62–1.40)	0.735	0.828	1.27(0.82–1.98)	0.280	0.970	1.10(0.73–1.64)	0.653	0.885	1.07(0.70–1.63)	0.753	0.791
		Additive	1.06(0.83–1.35)	0.665	0.820	1.10(0.86–1.41)	0.459	0.970	1.09(0.87–1.38)	0.450	0.855	1.07(0.83–1.38)	0.606	0.757
PPARG	rs2920503	Allele	1.00(0.77–1.30)	0.996	0.996	1.01(0.78–1.30)	0.970	0.970	1.05(0.82–1.34)	0.717	0.902	0.95(0.72–1.25)	0.705	0.762
		Co-dominant	1.15(0.61–2.17)	0.671	0.820	1.07(0.57–1.98)	0.840	0.970	1.18(0.65–2.14)	0.583	0.855	1.05(0.55–2.00)	0.878	0.883
			0.91(0.64–1.30)	0.604	0.794	0.91(0.63–1.31)	0.612	0.970	0.99(0.71–1.39)	0.971	0.971	0.84(0.58–1.23)	0.368	0.703
		Dominant	0.95(0.67–1.33)	0.749	0.828	0.94(0.66–1.33)	0.710	0.970	1.02(0.74–1.41)	0.891	0.959	0.88(0.61–1.25)	0.469	0.757
		Recessive	1.20(0.65–2.22)	0.561	0.794	1.11(0.61–2.02)	0.722	0.970	1.18(0.67–2.09)	0.561	0.855	1.14(0.61–2.11)	0.685	0.762
		Additive	1.00(0.77–1.31)	0.996	0.996	0.98(0.75–1.28)	0.900	0.970	1.05(0.82–1.35)	0.715	0.902	0.95(0.72–1.25)	0.708	0.762
PPARG	rs4073770	Allele	0.94(0.73–1.21)	0.605	0.794	1.05(0.82–1.35)	0.689	0.970	1.07(0.84–1.37)	0.573	0.855	0.90(0.69–1.18)	0.449	0.757
		Co-dominant	0.79(0.45–1.40)	0.414	0.669	0.86(0.50–1.50)	0.599	0.970	1.05(0.62–1.80)	0.848	0.960	0.63(0.35–1.12)	0.118	0.476
			1.02(0.71–1.46)	0.930	0.976	1.40(0.97–2.04)	0.076	0.970	1.17(0.83–1.65)	0.371	0.855	1.25(0.85–1.83)	0.256	0.580
		Dominant	0.97(0.68–1.36)	0.843	0.908	1.25(0.88–1.78)	0.206	0.970	1.14(0.83–1.58)	0.415	0.855	1.07(0.75–1.54)	0.704	0.762
		Recessive	0.78(0.46–1.34)	0.372	0.625	0.73(0.43–1.23)	0.237	0.970	0.98(0.59–1.62)	0.925	0.971	0.56(0.33–0.97)	0.038	0.476
		Additive	0.93(0.72–1.20)	0.569	0.794	1.04(0.81–1.34)	0.736	0.970	1.07(0.84–1.36)	0.575	0.855	0.91(0.70–1.18)	0.455	0.757
PPARG	rs1151988	Allele	0.78(0.54–1.12)	0.170	0.376	0.91(0.66–1.28)	0.599	0.970	0.96(0.69–1.33)	0.799	0.932	0.72(0.50–1.03)	0.074	0.476
		Co-dominant	0.52(0.09–3.20)	0.482	0.750	0.80(0.23–2.75)	0.723	0.970	0.71(0.19–2.68)	0.610	0.855	0.61(0.13–2.76)	0.520	0.757
			0.78(0.52–1.17)	0.224	0.424	0.91(0.61–1.35)	0.645	0.970	0.99(0.68–1.45)	0.969	0.971	0.69(0.46–1.04)	0.076	0.476
		Dominant	0.77(0.52–1.14)	0.191	0.382	0.9(0.62–1.33)	0.602	0.970	0.97(0.67–1.41)	0.885	0.960	0.68(0.46–1.02)	0.065	0.476
		Recessive	0.55(0.09–3.38)	0.523	0.785	0.82(0.24–2.81)	0.751	0.970	0.71(0.19–2.68)	0.611	0.855	0.67(0.15–3.03)	0.602	0.757
		Additive	0.77(0.53–1.12)	0.171	0.376	0.91(0.64–1.28)	0.577	0.970	0.96(0.68–1.34)	0.793	0.932	0.71(0.49–1.03)	0.068	0.476

SNP, single nucleotide polymorphism; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; FDR, false discovery rate.
Bold values indicate statistical significance (P < 0.05).

Back to article page

Table 3 Association of PPARD and PPARG polymorphisms with glioma risk stratified by age and sex.

Search

Quick links